<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.115354</article-id><article-id pub-id-type="publisher-id">ACM-42840</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210500000_43346677.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  左炔诺孕酮宫内释放系统用于治疗子宫内膜异位症的疗效和安全性Meta分析
  Levonorgestrel Releasing Intrauterine System for the Treatment of Endometriosis: A Meta-Analysis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>志琼</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>觇宇</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>罗</surname><given-names>美玲</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>重庆市江津区妇幼保健院妇科，重庆</addr-line></aff><aff id="aff3"><addr-line>重庆医科大学附属第二医院妇产科，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>05</month><year>2021</year></pub-date><volume>11</volume><issue>05</issue><fpage>2456</fpage><lpage>2466</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：采用循证医学方法评价左炔诺孕酮宫内释放系统节育器(levonorgestrel-releasing intrauterine system, LNG-IUS)治疗子宫内膜异位症的安全性及有效性。方法：通过计算机检索pubmed、embase、cochrane library等英文数据库及中国生物文献数据库、中国知网、维普、万方等中文数据库，检索时间由各大数据库建立至2021年2月，同时辅助其他检索方式，所检索文献由两名系统评价者独立评价纳入研究并提取资料，并用Revman软件进行meta分析。结果：共纳入14项研究，通过meta分析显示，与短效口服避孕药相比，LNG-IUS可明显缓解患者痛经程度(MD = −1.37, 95% CI = −2.17~−0.57, P = 0.0008)，降低血清CA125水平(MD = −4.76, 95% CI = −7.21~−2.32, P = 0.0001)，缩小子宫体积(SMD = −1.14, 95% CI = −2.24~−0.05, P = 0.04)，两者均有改善月经量的作用(MD = −10.64, 95% CI = −30.01~8.74, P &gt; 0.05)，但没有统计学差异；与促性腺激素释放激素激动剂相比，均有改善患者痛经和缩小子宫体积的作用(MD = −0.57, 95% CI = −1.34~0.2, P = 0.14; MD = −26.92, 95% CI = −28.03~20.85, P = 0.77)，但两者作用相当，没有明显统计学差异。但是GnRH-a在使用过程中出现不良反应的概率明显高于LNG-IUS (OR = 0.19, 95% CI = 0.09~0.44, P &lt; 0.00001)，且在减少月经量方面没有LNG-IUS有效(MD = −13.39, 95% CI = −22.2~−4.58, P = 0.003)；而在与孕三烯酮对比过程中发现，LNG-IUS在改善痛经程度(MD = −0.63, 95% CI = −0.95~−0.31, P = 0.001)、缩小子宫体积(SMD = −1.38, 95% CI = −2.31~−0.46, P = 0.003)、减少月经量(MD = −20.27, 95% CI = −26.1~−14.52, P &lt; 0.00001)方面均优于孕三烯酮，且不良反应更少(OR = 0.19, 95% CI = 0.09~0.44, P &lt; 0.00001)。结论：LNG-IUS对子宫内膜异位症的治疗效果较其他药物治疗更为显著，不良反应减少，在暂无生育要求且无LNG-IUS禁忌症患者中可作为首选。
   Objective: To evaluated the safety and efficacy of levonorgestrel releasing intrauterine system (LNG-IUS) in the treatment of endometriosis by evidence-based medicine. Methods: English databases such as PubMed, EMBASE, Cochrane Library and Chinese databases such as China biological literature database, CNKI, VIP, Wanfang were searched by computer. The retrieval time is from the establishment of major databases to February 2021. The retrieved articles were independently evaluated by two reviewers. The data were extracted and meta-analysis was performed by Revman software. Results: There are 14 studies were included. Meta analysis showed that compared with oral contraceptives, LNG-IUS could significantly relieve dysmenorrhea (MD = −1.37, 95% CI = −2.17~−0.57, P = 0.0008), reduce serum CA125 level (MD = −4.76, 95% CI = −7.21~−2.32, P = 0.0001), reduce uterine volume (SMD = −1.14, 95% CI = −2.24~−0.05, P = 0.04). And both of them could improve menstrual volume with no statistical difference (MD = −1.14, 95% CI = −2.24~−0.05, P = 0.04). Compared with gonadotropin-releasing hormone, LNG-IUS had the same effect of improvin dysmenorrhea and reducing uterine volume (MD= −0.57, 95% CI= −1.34~0.2, P= 0.14; MD= −26.92, 95% CI = −28.03~20.85, P = 0.77), lower incidence of adverse reactions (OR = 0.19, 95% CI = 0.09~0.44, P &lt; 0.00001) and better effect of reducing menstruation (MD = −13.39, 95% CI = −22.2~−4.58, P = 0.003). Compared with gestrinone, LNG-IUS was superior to gestrinone in improving dysmenorrhea (MD = −0.63, 95% CI = −0.95~−0.31, P = 0.001), reducing uterine volume (SMD = −1.38, 95% CI = −2.31~−0.46, P = 0.003) and reducing menstrual volume (MD = −20.27, 95% CI = −26.1~−14.52, P &lt; 0.00001) with fewer adverse reactions (OR = 0.19, 95% CI = 0.09~0.44, P &lt; 0.00001). Conclusion: LNG-IUS was more effective than other drugs in the treatment of endometriosis, with less adverse reactions. It could be used as the first choice in patients with no fertility requirements or no contraindications of LNG-IUS.
 
</p></abstract><kwd-group><kwd>左炔诺孕酮宫内释放系统，子宫内膜异位症，Meta分析，短效口服避孕药，促性腺激素释放激素激动剂，孕三烯酮, Levonorgestrel-Releasing Intrauterine System</kwd><kwd> Endometriosis</kwd><kwd> Meta Analysis</kwd><kwd> Oral Contraceptives</kwd><kwd> Gonadotropin-Releasing Hormone</kwd><kwd> Gestrinone</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：采用循证医学方法评价左炔诺孕酮宫内释放系统节育器(levonorgestrel-releasing intrauterine system, LNG-IUS)治疗子宫内膜异位症的安全性及有效性。方法：通过计算机检索pubmed、embase、cochrane library等英文数据库及中国生物文献数据库、中国知网、维普、万方等中文数据库，检索时间由各大数据库建立至2021年2月，同时辅助其他检索方式，所检索文献由两名系统评价者独立评价纳入研究并提取资料，并用Revman软件进行meta分析。结果：共纳入14项研究，通过meta分析显示，与短效口服避孕药相比，LNG-IUS可明显缓解患者痛经程度(MD = −1.37, 95% CI = −2.17~−0.57, P = 0.0008)，降低血清CA125水平(MD = −4.76, 95% CI = −7.21~−2.32, P = 0.0001)，缩小子宫体积(SMD = −1.14, 95% CI = −2.24~−0.05, P = 0.04)，两者均有改善月经量的作用(MD = −10.64, 95% CI = −30.01~8.74, P &gt; 0.05)，但没有统计学差异；与促性腺激素释放激素激动剂相比，均有改善患者痛经和缩小子宫体积的作用(MD = −0.57, 95% CI = −1.34~0.2, P = 0.14; MD = −26.92, 95% CI = −28.03~20.85, P = 0.77)，但两者作用相当，没有明显统计学差异。但是GnRH-a在使用过程中出现不良反应的概率明显高于LNG-IUS (OR = 0.19, 95% CI = 0.09~0.44, P &lt; 0.00001)，且在减少月经量方面没有LNG-IUS有效(MD = −13.39, 95% CI = −22.2~−4.58, P = 0.003)；而在与孕三烯酮对比过程中发现，LNG-IUS在改善痛经程度(MD = −0.63, 95% CI = −0.95~−0.31, P = 0.001)、缩小子宫体积(SMD = −1.38, 95% CI = −2.31~−0.46, P = 0.003)、减少月经量(MD = −20.27, 95% CI = −26.1~−14.52, P &lt; 0.00001)方面均优于孕三烯酮，且不良反应更少(OR = 0.19, 95% CI = 0.09~0.44, P &lt; 0.00001)。结论：LNG-IUS对子宫内膜异位症的治疗效果较其他药物治疗更为显著，不良反应减少，在暂无生育要求且无LNG-IUS禁忌症患者中可作为首选。</p></sec><sec id="s2"><title>关键词</title><p>左炔诺孕酮宫内释放系统，子宫内膜异位症，Meta分析，短效口服避孕药，促性腺激素释放激素激动剂，孕三烯酮</p></sec><sec id="s3"><title>Levonorgestrel Releasing Intrauterine System for the Treatment of Endometriosis: A Meta-Analysis<sup> </sup></title><p>Zhiqiong Zhang<sup>1*</sup>, Chanyu Zhang<sup>2</sup>, Meiling Luo<sup>2#</sup></p><p><sup>1</sup>Department of Gynaecology, Jiangjin Maternal and Child Health Hospital in Chongqing, Chongqing</p><p><sup>2</sup>Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing</p><p><img src="//html.hanspub.org/file/63-1572212x5_hanspub.png" /></p><p>Received: Apr. 27<sup>th</sup>, 2021; accepted: May 11<sup>th</sup>, 2021; published: May 31<sup>st</sup>, 2021</p><p><img src="//html.hanspub.org/file/63-1572212x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To evaluated the safety and efficacy of levonorgestrel releasing intrauterine system (LNG-IUS) in the treatment of endometriosis by evidence-based medicine. Methods: English databases such as PubMed, EMBASE, Cochrane Library and Chinese databases such as China biological literature database, CNKI, VIP, Wanfang were searched by computer. The retrieval time is from the establishment of major databases to February 2021. The retrieved articles were independently evaluated by two reviewers. The data were extracted and meta-analysis was performed by Revman software. Results: There are 14 studies were included. Meta analysis showed that compared with oral contraceptives, LNG-IUS could significantly relieve dysmenorrhea (MD = −1.37, 95% CI = −2.17~−0.57, P = 0.0008), reduce serum CA125 level (MD = −4.76, 95% CI = −7.21~−2.32, P = 0.0001), reduce uterine volume (SMD = −1.14, 95% CI = −2.24~−0.05, P = 0.04). And both of them could improve menstrual volume with no statistical difference (MD = −1.14, 95% CI = −2.24~−0.05, P = 0.04). Compared with gonadotropin-releasing hormone, LNG-IUS had the same effect of improvin dysmenorrhea and reducing uterine volume (MD= −0.57, 95% CI= −1.34~0.2, P= 0.14; MD= −26.92, 95% CI = −28.03~20.85, P = 0.77), lower incidence of adverse reactions (OR = 0.19, 95% CI = 0.09~0.44, P &lt; 0.00001) and better effect of reducing menstruation (MD = −13.39, 95% CI = −22.2~−4.58, P = 0.003). Compared with gestrinone, LNG-IUS was superior to gestrinone in improving dysmenorrhea (MD = −0.63, 95% CI = −0.95~−0.31, P = 0.001), reducing uterine volume (SMD = −1.38, 95% CI = −2.31~−0.46, P = 0.003) and reducing menstrual volume (MD = −20.27, 95% CI = −26.1~−14.52, P &lt; 0.00001) with fewer adverse reactions (OR = 0.19, 95% CI = 0.09~0.44, P &lt; 0.00001). Conclusion: LNG-IUS was more effective than other drugs in the treatment of endometriosis, with less adverse reactions. It could be used as the first choice in patients with no fertility requirements or no contraindications of LNG-IUS.</p><p>Keywords:Levonorgestrel-Releasing Intrauterine System, Endometriosis, Meta Analysis, Oral Contraceptives, Gonadotropin-Releasing Hormone, Gestrinone</p><disp-formula id="hanspub.42840-formula47"><graphic xlink:href="//html.hanspub.org/file/63-1572212x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/63-1572212x8_hanspub.png" /> <img src="//html.hanspub.org/file/63-1572212x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>子宫内膜异位症是最常见的妇科疾病之一，通常伴有痛经、盆腔疼痛、性交困难、腹胀和肠易激综合征、生育力下降和不孕等症状，对患者的正常生活及工作造成影响 [<xref ref-type="bibr" rid="hanspub.42840-ref1">1</xref>]。其发病机制尚不明确，但是目前被认可较多的是子宫内膜异位症是一种雌激素依赖性疾病，因此对于子宫内膜异位症的治疗需根据患者年龄、症状严重程度、病变部位以及有无生育要求进行全方面评估，制定个体化治疗方案 [<xref ref-type="bibr" rid="hanspub.42840-ref2">2</xref>]。目前常用的药物有促性腺激素释放激素(gonadotropin-releasing hormone, GnRH)激动剂、孕激素、短效口服避孕药以及非甾体类抗炎药等，目前指南推荐一线用药为孕激素，但使用周期长，使用方式较为复杂，且使用孕激素过程中无生育要求的育龄期妇女需进行避孕，因此LNG-IUS (商品名为曼月乐)作为节育器既可以达到良好的避孕效果，也可缓解痛经，减少月经量，并且由于LNG-IUS中孕激素仅作用于内膜，相对于其他用药来讲，全身副作用大大减少。为进一步研究LNG-IUS对于子宫内膜异位症的疗效，本研究收集多个LNG-IUS用于治疗子宫内膜异位症的相关随机对照实验进行总结，以期对临床医生合理应用及推广LNG-IUS提供可靠的依据。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 文献检索</title><p>以endometriosis、adenomyosis和levonorgestrel releasing intrauterine system、LNG-IUS为主题词 + 自由词检索方式，检索Pubmed、embase及cochrane library等英文数据库；以子宫内膜异位症，子宫腺肌症和曼月乐，左炔诺孕酮宫内缓释系统为主题词 + 自由词检索方式，检索中国医学数字图书馆、万方医学网、维普网以及中国生物医学文献服务系统等中文数据库，并运用手工检索，全面搜索国内外相关文献。</p></sec><sec id="s6_2"><title>2.2. 文献纳入和排除标准</title><p>1) 纳入标准：① 研究对象：符合《子宫内膜异位症诊治指南》中子宫内膜异位症诊断标准的患者；② 研究类型：需为临床对照试验或随机对照试验，且需具有全部原始数据；③ 干预措施：实验组为放置LNG-IUS，对照组为口服短效口服避孕药或孕三烯酮或肌注GnRH-a；④ 结局指标：疼痛程度(参照疼痛视觉模拟评分法)改变；月经量；血清CA125水平；不良反应发生率；子宫体积。</p><p>2) 排除标准：摘要，会议，综述，讲座，自身前后对照试验，相关数据不完整，或对照组采用手术治疗或其他治疗方式的相关对照试验。</p></sec><sec id="s6_3"><title>2.3. 研究筛选及资料提取</title><p>由两名评价员独立对文献进严格按照纳入标准和排除标准行筛选和质量评价，而后交叉对比结果，如遇分歧即进行讨论或由第三名评价者仲裁决定。资料提取包括：一般资料：作者姓名，出版日期，题目和文献来源；研究特征：研究对象的一般特征，各组患者的基线可比性，干预措施；结局指标：疼痛程度(参照疼痛视觉模拟评分法)改变；月经量；血清CA125水平；不良反应发生率；子宫体积。</p></sec><sec id="s6_4"><title>2.4. 质量评价</title><p>纳入研究的方法学质量采用cochrane系统评价员手册随机对照试验的四条质量评价标准进行评价，评价内容包括对照方法、分配隐藏、盲法和退出。</p></sec><sec id="s6_5"><title>2.5. 统计分析</title><p>采用Revman 5.4软件进行meta分析，计数资料采用比值比(OR)分析统计量，计量资料采用均数差(MD)或标准化均数差(SMD)分析统计量，若某类计量资料度衡量单位一致时，采用均数差和95%可信区间(95%CI)表示，若度衡量单位不一致，则使用标准化均数差和95%可信区间(95%CI)表示，若并绘制森林图。各纳入结果的异质性分析，若各研究间具有显著异质性，即I2 ≥ 50%，分析其异质性来源，并使用随机效应模型进行分析，同时对明显异质性进行敏感性分析。反之若各研究间无异质性，即I2 &lt; 50%，则采用固定效应模型。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 文献检索情况</title><p>初检索出相关文献2013篇，通过阅读题目、摘要剔除，剩余文献43篇，再通过精读文献剔除不符合标准的文献，其中自身前后对照3篇，对照组非药物治疗20篇，失访病例超过20% 3篇，最终纳入文献17篇 [<xref ref-type="bibr" rid="hanspub.42840-ref3">3</xref>] - [<xref ref-type="bibr" rid="hanspub.42840-ref19">19</xref>]。纳入文献基本特征详见表1，质量评价见表2。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Basic characteristics of included studie</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >纳入研究</th><th align="center" valign="middle"  rowspan="2"  >例数</th><th align="center" valign="middle"  rowspan="2"  >年龄</th><th align="center" valign="middle"  colspan="2"  >干预措施</th><th align="center" valign="middle"  rowspan="2"  >结局指标</th></tr></thead><tr><td align="center" valign="middle" >试验组</td><td align="center" valign="middle" >对照组</td></tr><tr><td align="center" valign="middle" >Omar M. Shaaban</td><td align="center" valign="middle" >29/28</td><td align="center" valign="middle" >39.39 &#177; 4.43/39.16 &#177; 3.21</td><td align="center" valign="middle" >LNG-IUS</td><td align="center" valign="middle" >口服避孕药</td><td align="center" valign="middle" >①②</td></tr><tr><td align="center" valign="middle" >刘志红</td><td align="center" valign="middle" >35/32</td><td align="center" valign="middle" >28.54 &#177; 1.78/29.72 &#177; 1.64</td><td align="center" valign="middle" >LNG-IUS</td><td align="center" valign="middle" >口服避孕药</td><td align="center" valign="middle" >①③</td></tr><tr><td align="center" valign="middle" >王海清</td><td align="center" valign="middle" >58/48</td><td align="center" valign="middle" >33.21 &#177; 2.53/31.45 &#177; 3.52</td><td align="center" valign="middle" >LNG-IUS</td><td align="center" valign="middle" >口服避孕药</td><td align="center" valign="middle" >①②③④⑤</td></tr><tr><td align="center" valign="middle" >王红</td><td align="center" valign="middle" >54/53</td><td align="center" valign="middle" >32.6 &#177; 3.8/31.8 &#177; 3.6</td><td align="center" valign="middle" >LNG-IUS</td><td align="center" valign="middle" >口服避孕药</td><td align="center" valign="middle" >①②③④</td></tr><tr><td align="center" valign="middle" >金亚玲</td><td align="center" valign="middle" >39/39</td><td align="center" valign="middle" >29.55 &#177; 2.53/29.53 &#177; 2.52</td><td align="center" valign="middle" >LNG-IUS</td><td align="center" valign="middle" >口服避孕药</td><td align="center" valign="middle" >①②</td></tr><tr><td align="center" valign="middle" >陈小梅</td><td align="center" valign="middle" >49/49</td><td align="center" valign="middle" >30.28 &#177; 1.42/30.21 &#177; 1.45</td><td align="center" valign="middle" >LNG-IUS</td><td align="center" valign="middle" >口服避孕药</td><td align="center" valign="middle" >①②④</td></tr><tr><td align="center" valign="middle" >黄立冬</td><td align="center" valign="middle" >31/31</td><td align="center" valign="middle" >39.39 &#177; 4.43/39.16 &#177; 3.21</td><td align="center" valign="middle" >LNG-IUS</td><td align="center" valign="middle" >口服避孕药</td><td align="center" valign="middle" >①②⑤</td></tr><tr><td align="center" valign="middle" >丁秀娟</td><td align="center" valign="middle" >45/44</td><td align="center" valign="middle" >36.34 &#177; 4.21/36.27 &#177; 4.15</td><td align="center" valign="middle" >LNG-IUS</td><td align="center" valign="middle" >GnRH-a</td><td align="center" valign="middle" >①②④</td></tr><tr><td align="center" valign="middle" >周妍</td><td align="center" valign="middle" >36/36</td><td align="center" valign="middle" >37.3 &#177; 7.5/36.7 &#177; 8.8</td><td align="center" valign="middle" >LNG-IUS</td><td align="center" valign="middle" >GnRH-a</td><td align="center" valign="middle" >①②④</td></tr><tr><td align="center" valign="middle" >栾莹</td><td align="center" valign="middle" >30/30</td><td align="center" valign="middle" >36.15 &#177; 3.48/37.34 &#177; 3.51</td><td align="center" valign="middle" >LNG-IUS</td><td align="center" valign="middle" >GnRH-a</td><td align="center" valign="middle" >①</td></tr><tr><td align="center" valign="middle" >王笑妍</td><td align="center" valign="middle" >28/25</td><td align="center" valign="middle" >35.6 &#177; 4.5/34.7 &#177; 4.8</td><td align="center" valign="middle" >LNG-IUS</td><td align="center" valign="middle" >GnRH-a</td><td align="center" valign="middle" >①②③⑤</td></tr><tr><td align="center" valign="middle" >黄彦</td><td align="center" valign="middle" >20/20</td><td align="center" valign="middle" >31.65 &#177; 3.44/32.05 &#177; 3.06</td><td align="center" valign="middle" >LNG-IUS</td><td align="center" valign="middle" >GnRH-a</td><td align="center" valign="middle" >①②④⑤</td></tr><tr><td align="center" valign="middle" >廖红</td><td align="center" valign="middle" >34/34</td><td align="center" valign="middle" >32.41 &#177; 6.12/32.51 &#177; 6.24</td><td align="center" valign="middle" >LNG-IUS</td><td align="center" valign="middle" >孕三烯酮</td><td align="center" valign="middle" >①②④⑤</td></tr><tr><td align="center" valign="middle" >李文娟</td><td align="center" valign="middle" >41/41</td><td align="center" valign="middle" >37.25 &#177; 4.26/37.31 &#177; 4.57</td><td align="center" valign="middle" >LNG-IUS</td><td align="center" valign="middle" >孕三烯酮</td><td align="center" valign="middle" >①②⑤</td></tr><tr><td align="center" valign="middle" >蓝继常</td><td align="center" valign="middle" >30/30</td><td align="center" valign="middle" >35.61 &#177; 5.31/35.69 &#177; 5.87</td><td align="center" valign="middle" >LNG-IUS</td><td align="center" valign="middle" >孕三烯酮</td><td align="center" valign="middle" >①②③④⑤</td></tr><tr><td align="center" valign="middle" >马晓惠</td><td align="center" valign="middle" >45/45</td><td align="center" valign="middle" >35(27~42)/35.5(28~40)</td><td align="center" valign="middle" >LNG-IUS</td><td align="center" valign="middle" >孕三烯酮</td><td align="center" valign="middle" >①②④⑤</td></tr><tr><td align="center" valign="middle" >杨益琴</td><td align="center" valign="middle" >41/41</td><td align="center" valign="middle" >40.9 &#177; 6.7/40.3 &#177; 6.9</td><td align="center" valign="middle" >LNG-IUS</td><td align="center" valign="middle" >孕三烯酮</td><td align="center" valign="middle" >②⑤</td></tr></tbody></table></table-wrap><p>表1. 纳入研究的基本特征</p><p>① 痛经程度(参照疼痛视觉模拟评分法)改变；② 月经量；③ 血清CA125水平；④ 不良反应发生率；⑤ 子宫体积。</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Quality evaluation of included studie</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" >纳入研究</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >随机方法</th><th align="center" valign="middle" >分配隐藏</th><th align="center" valign="middle" >盲法</th><th align="center" valign="middle" >退出</th><th align="center" valign="middle" >随访时间</th></tr></thead><tr><td align="center" valign="middle" >Omar M. Shaaban</td><td align="center" valign="middle" >29/28</td><td align="center" valign="middle" >随机表</td><td align="center" valign="middle" >避光信封</td><td align="center" valign="middle" >双盲</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >1、3、6</td></tr><tr><td align="center" valign="middle" >刘志红</td><td align="center" valign="middle" >35/32</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >治疗后</td></tr><tr><td align="center" valign="middle" >王海清</td><td align="center" valign="middle" >58/48</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >王红</th><th align="center" valign="middle" >54/53</th><th align="center" valign="middle" >不清楚</th><th align="center" valign="middle" >无</th><th align="center" valign="middle" >无</th><th align="center" valign="middle" >无</th><th align="center" valign="middle" >3、6</th></tr></thead><tr><td align="center" valign="middle" >金亚玲</td><td align="center" valign="middle" >39/39</td><td align="center" valign="middle" >信封随机分组</td><td align="center" valign="middle" >不透明信封</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >1、2、3</td></tr><tr><td align="center" valign="middle" >陈小梅</td><td align="center" valign="middle" >49/49</td><td align="center" valign="middle" >入院顺序</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >黄立冬</td><td align="center" valign="middle" >31/31</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >丁秀娟</td><td align="center" valign="middle" >45/44</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >6、12</td></tr><tr><td align="center" valign="middle" >周妍</td><td align="center" valign="middle" >36/36</td><td align="center" valign="middle" >随机表</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >6、12</td></tr><tr><td align="center" valign="middle" >栾莹</td><td align="center" valign="middle" >30/30</td><td align="center" valign="middle" >随机表</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >王笑妍</td><td align="center" valign="middle" >28/25</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >3、6、12、24</td></tr><tr><td align="center" valign="middle" >黄彦</td><td align="center" valign="middle" >20/20</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >3、6、12</td></tr><tr><td align="center" valign="middle" >廖红</td><td align="center" valign="middle" >34/34</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >李文娟</td><td align="center" valign="middle" >41/41</td><td align="center" valign="middle" >红绿双色球</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >蓝继常</td><td align="center" valign="middle" >30/30</td><td align="center" valign="middle" >入院顺序</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >马晓惠</td><td align="center" valign="middle" >45/45</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >杨益琴</td><td align="center" valign="middle" >41/41</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >3、6</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. 纳入研究的质量评价</p></sec><sec id="s7_2"><title>3.2. 疗效分析</title><sec id="s7_2_1"><title>3.2.1. LNG-IUS与口短效服避孕药</title><p>共7篇文献 [<xref ref-type="bibr" rid="hanspub.42840-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref17">17</xref>] 对这两种治疗方式进行了对比，提取数据进行合并分析，LNG-IUS组共295例，口服避孕药组共280例，这７篇文章均对痛经程度VAS评分进行了分析，其异质性检验结果为P &lt; 0.00001，I<sup>2</sup> = 98%，故采用随机效应模型合并效应量为：MD = −1.4，95%CI = −2.10~−0.61，P = 0.005，说明LNG-IUS在改善痛经程度方面优于短效口服避孕药。有3篇文章 [<xref ref-type="bibr" rid="hanspub.42840-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref17">17</xref>] 分析了两组在减少月经量方面的差异，其结果为异质性检验结果为异质性检验结果为P &lt; 0.00001，I<sup>2</sup> = 99%，采用随机效应模型合并效应量为：MD = −10.64，95%CI = −30.01~8.74，P &gt; 0.05，LNG-IUS与短效口服避孕药均能减少患者月经量，且具有类似的效果。而在降低血清CA125水平方面，有4篇文章 [<xref ref-type="bibr" rid="hanspub.42840-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref17">17</xref>] 对比了两种治疗方式在随访第6个月时的效果，但各研究间存在明显异质性(I<sup>2</sup> = 95%)，采用随机效应模型合并分析结果显示：MD = −4.76，95%CI = −7.21~−2.32，P = 0.0001，与短效口服避孕药相比，使用LNG-IUS患者中血清CA125水平下降更明显。有2篇文章 [<xref ref-type="bibr" rid="hanspub.42840-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref16">16</xref>] 则报道了两者在缩小子宫内膜异位症患者子宫体积方面的作用，异质性检验为：P = 0.43，I<sup>2</sup> = 0%，经固定效应模型分析得出：MD = −0.69，95%CI = −1.05~−0.32，P = 0.0002，由此可以看出使用LNG-IUS较短效口服避孕药来讲，缩小子宫体积的作用更佳。而针对两者的不良反应发生率，仅1篇文章进行了报道，故没有进行合并分析。见表3、图1。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> LNG-IUS and short acting oral contraceptive</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >结局指标</th><th align="center" valign="middle" >纳入研究数</th><th align="center" valign="middle"  colspan="2"  >异质性检验结果</th><th align="center" valign="middle" >效应模式</th><th align="center" valign="middle"  colspan="3"  >Meta分析结果</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >I<sup>2</sup> (%)</td><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >MD/SMD/OR</td><td align="center" valign="middle" >95%CI</td><td align="center" valign="middle" >P值</td></tr><tr><td align="center" valign="middle" >痛经程度</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >98</td><td align="center" valign="middle" >&lt;0.0001</td><td align="center" valign="middle" >随机</td><td align="center" valign="middle" >−1.4</td><td align="center" valign="middle" >−2.1，−0.6</td><td align="center" valign="middle" >0.005</td></tr><tr><td align="center" valign="middle" >月经量</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >99</td><td align="center" valign="middle" >&lt;0.0001</td><td align="center" valign="middle" >随机</td><td align="center" valign="middle" >−10.64</td><td align="center" valign="middle" >−30.01，8.74</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >CA125</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >95</td><td align="center" valign="middle" >&lt;0.0001</td><td align="center" valign="middle" >随机</td><td align="center" valign="middle" >−4.76</td><td align="center" valign="middle" >−7.21，−2.32</td><td align="center" valign="middle" >0.0001</td></tr><tr><td align="center" valign="middle" >子宫体积</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.43</td><td align="center" valign="middle" >固定</td><td align="center" valign="middle" >−0.69</td><td align="center" valign="middle" >−1.05，−0.32</td><td align="center" valign="middle" >0.0002</td></tr></tbody></table></table-wrap><p>表3. LNG-IUS与短效口服避孕药</p><p>图1. LNG-IUS与短效口服避孕药的meta分析图</p></sec><sec id="s7_2_2"><title>3.2.2. LNG-IUS与GnRH-a</title><p>共5篇文章 [<xref ref-type="bibr" rid="hanspub.42840-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref19">19</xref>] 对LNG-IUS及GnRH进行了对比，LNG-IUS组共159例，GnRH-a组共155例。这5篇文章针对两种治疗方式在痛经程度VAS评分进行了对比，异质性检验结果为P &lt; 0.00001，I<sup>2</sup> = 98%，采用随机效应模型合并效应量为：MD = −0.57，95%CI = −1.34~0.2，P = 0.14，两组在改善痛经程度方面无统计学差异，LNG-IUS可以较好的改善患者痛经，其效果与GnRH-a一致。其中有4篇文章 [<xref ref-type="bibr" rid="hanspub.42840-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref19">19</xref>] 对月经量变化进行了报道，提取数据进行分析显示第6个月两组月经量变化两组间无明显差异(P &lt; 0.00001, I<sup>2</sup> = 94%; MD = −2.96, 95%CI = −9.09~3.17, P = 0.34)，而在第12个月的随访结果中发现放置LNG-IUS的患者较GnRH-a组患者月经量明显减少，异质性检验结果为P &lt; 0.00001，I<sup>2</sup> = 98%，采用随机效应模型合并效应量为：MD = −13.39，95%CI = −22.2~−4.58，P = 0.003。而仅2篇文章 [<xref ref-type="bibr" rid="hanspub.42840-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref19">19</xref>] 在子宫体积变化方面将两者进行了对比，合并数据得出结果：MD = −3.59，95%CI = −28.03~20.85，P = 0.23，两者在缩小子宫体积效果方面没有统计学差异。此外有3篇文献 [<xref ref-type="bibr" rid="hanspub.42840-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref18">18</xref>] 对两者的不良反应发生率进行了分析，合并分析结果为：异质性检验为：P = 0.87，I<sup>2</sup> = 0%，遂采用固定效应模型合并效应量为：OR = 0.19，95%CI = 0.09~0.44，P &lt; 0.00001，在不良反应发生率这一方面，GnRH-a明显高于LNG-IUS。见表4、图2。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> LNG-IUS and GnRH-</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >结局指标</th><th align="center" valign="middle" >纳入研究</th><th align="center" valign="middle"  colspan="2"  >异质性检验结果</th><th align="center" valign="middle" >效应模式</th><th align="center" valign="middle"  colspan="3"  >Meta分析结果</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >数</td><td align="center" valign="middle" >I<sup>2</sup> (%)</td><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >MD/SMD/OR</td><td align="center" valign="middle" >95%CI</td><td align="center" valign="middle" >P值</td></tr><tr><td align="center" valign="middle" >痛经程度</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >98</td><td align="center" valign="middle" >&lt;0.0001</td><td align="center" valign="middle" >随机</td><td align="center" valign="middle" >−0.57</td><td align="center" valign="middle" >−1.34，−0.2</td><td align="center" valign="middle" >0.14</td></tr><tr><td align="center" valign="middle" >月经量(6)</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >94</td><td align="center" valign="middle" >&lt;0.0001</td><td align="center" valign="middle" >随机</td><td align="center" valign="middle" >−2.96</td><td align="center" valign="middle" >−9.09，3.17</td><td align="center" valign="middle" >0.34</td></tr><tr><td align="center" valign="middle" >月经量(12)</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >98</td><td align="center" valign="middle" >&lt;0.0001</td><td align="center" valign="middle" >随机</td><td align="center" valign="middle" >−13.39</td><td align="center" valign="middle" >−22.2，−4.58</td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >子宫体积</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >95</td><td align="center" valign="middle" >&lt;0.0001</td><td align="center" valign="middle" >随机</td><td align="center" valign="middle" >−3.59</td><td align="center" valign="middle" >−28.03，20.85</td><td align="center" valign="middle" >0.66</td></tr><tr><td align="center" valign="middle" >不良反应</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.87</td><td align="center" valign="middle" >固定</td><td align="center" valign="middle" >−0.19</td><td align="center" valign="middle" >0.09，−0.44</td><td align="center" valign="middle" >&lt;0.0001</td></tr></tbody></table></table-wrap><p>表4. LNG-IUS与GnRH-a</p><p>图2. LNG-IUS与GnRH-a的meta分析图</p></sec><sec id="s7_2_3"><title>3.2.3. LNG-IUS与孕三烯酮</title><p>检索文献中有5篇文献 [<xref ref-type="bibr" rid="hanspub.42840-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref15">15</xref>] 对LNG-IUS及孕三烯酮进行了比对，其中4篇文献 [<xref ref-type="bibr" rid="hanspub.42840-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref15">15</xref>] 对痛经程度进行了报道，合并数据得出结果：异质性检验结果为：P &lt; 0.00001，I<sup>2</sup> = 95%，采用随机效应模型合并效应量：MD = −0.63，95%CI = −0.95~−0.31，P = 0.001，由此结果可以看出LNG-IUS在减轻患者痛经程度方面较孕三烯酮更加有效。针对月经量方面的变化，5篇文献均进行了报道，meta分析结果为：异质性检验为：P &lt; 0.00001，I<sup>2</sup> = 94%，随机效应模型合并效应量：MD = −20.27，95%CI = −26.1~−14.52，P &lt; 0.00001，使用LNG-IUS后月经量较口服孕三烯酮明显减少，其差异具有统计学差异。此外这5篇文献还报道了两者在子宫体积方面的改变，异质性检验结果为：P &lt; 0.00001，I<sup>2</sup> = 94%，采用随机效应模型对效应量进行合并：SMD = −1.38，95%CI = −2.31~−0.46，P = 0.003，治疗后LNG-IUS组子宫体积明显小于孕三烯酮组。针对不良发生率方面，仅3篇文献 [<xref ref-type="bibr" rid="hanspub.42840-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.42840-ref15">15</xref>] 将两种治疗方式进行了对比，合并数据后异质性检验结果为：P＝0.33，I<sup>2</sup> = 0%，遂采用固定效应模型合并效应量结果为：OR = 0.19，95%CI = 0.09~0.44，P &lt; 0.00001，LNG-IUS在治疗过程中出现的不良反应较口服孕三烯酮更少。见表5、图3。</p><p>图3. LNG-IUS与孕三烯酮的meta分析图</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> LNG-IUS and Gestrinon</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >结局指标</th><th align="center" valign="middle" >纳入研究数</th><th align="center" valign="middle"  colspan="2"  >异质性检验结果</th><th align="center" valign="middle" >效应模式</th><th align="center" valign="middle"  colspan="3"  >Meta分析结果</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >I<sup>2</sup> (%)</td><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >MD/SMD/OR</td><td align="center" valign="middle" >95%CI</td><td align="center" valign="middle" >P值</td></tr><tr><td align="center" valign="middle" >痛经程度</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >95</td><td align="center" valign="middle" >&lt;0.0001</td><td align="center" valign="middle" >随机</td><td align="center" valign="middle" >−0.63</td><td align="center" valign="middle" >−0.95，−0.31</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >月经量</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >94</td><td align="center" valign="middle" >&lt;0.0001</td><td align="center" valign="middle" >随机</td><td align="center" valign="middle" >−20.27</td><td align="center" valign="middle" >−26.1，−14.52</td><td align="center" valign="middle" >&lt;0.0001</td></tr><tr><td align="center" valign="middle" >子宫体积</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >94</td><td align="center" valign="middle" >&lt;0.0001</td><td align="center" valign="middle" >随机</td><td align="center" valign="middle" >−1.38</td><td align="center" valign="middle" >−2.31，−0.46</td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >不良反应</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.33</td><td align="center" valign="middle" >固定</td><td align="center" valign="middle" >0.19</td><td align="center" valign="middle" >0.09，0.44</td><td align="center" valign="middle" >&lt;0.0001</td></tr></tbody></table></table-wrap><p>表5. LNG-IUS与孕三烯酮</p></sec></sec><sec id="s7_3"><title>3.3. 敏感性分析</title><p>为了评估异质性来源及稳定性，本文通过逐一剔除法剔除异质性最大的研究后进行敏感性分析，其结果与之前研究相一致，提示结果是相对稳定的，见图4。</p><p>图4. LNG-IUS与短效口服避孕药痛经程度比较的敏感性分析</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>子宫内膜异位症最常见的症状为痛经和慢性盆腔痛，严重者影响生活与工作，尽管腹腔镜手术被列为治疗子宫内膜异位症的首选甚至是确诊的金标准。但是研究 [<xref ref-type="bibr" rid="hanspub.42840-ref20">20</xref>] 表明，手术后5年内随访患者症状减轻情况与使用LNG-IUS的差异无统计学意义，且轻症患者不建议手术治疗，因此药物治疗对于部分人群来说非常重要。子宫内膜异位症药物治疗的主要目的在于抑制卵巢功能，阻止内异症的发展。LNG-IUS是一种持续高效释放孕激素的新型宫内节育系统，作用时间可持续5年，克服了传统药物治疗长期规律使用、全身不良反应多、耐受性及依从性差等缺点，其作用原理在于少量孕激素持续作用于子宫内膜，使子宫内膜萎缩，处于薄子宫内膜状态，在避孕的同时可以达到治疗子宫内膜异位症的效果，目前在临床上得到了广泛的使用 [<xref ref-type="bibr" rid="hanspub.42840-ref21">21</xref>]。已经有较多文献报道了LNG-IUS对子宫内膜异位症的治疗作用，但是结果存在一定的差异，因此本研究通过循证医学角度，综合各个高质量文献进行研究，得出一个较为理想的结果。</p><p>本研究结果显示LNG-IUS与GnRH-a在子宫内膜异位症患者中均有改善患者痛经和缩小子宫体积的作用，但两者作用相当，没有明显统计学差异。但是GnRH-a在使用过程中出现不良反应的概率明显高于LNG-IUS，且在减少月经量方面没有LNG-IUS有效，主要因为LNG-IUS中释放的孕激素局部作用于子宫内膜，拮抗雌激素作用，促进细胞凋亡，使内膜萎缩，或者直接下调雌激素受体，起到缩小病灶，提高子宫收缩性，减少月经量的作用 [<xref ref-type="bibr" rid="hanspub.42840-ref7">7</xref>]。而GnRH-a主要作用于促性腺激素释放激素受体，一过性刺激促性腺激素分泌后则抑制促性腺激素释放，从而抑制性激素的分泌，使异位的子宫内膜处于休息状态，但此药物价格昂贵，且作用于全身，导致患者出现围绝经期症状或骨质疏松等不良反应 [<xref ref-type="bibr" rid="hanspub.42840-ref2">2</xref>]。此外近年来短效口服避孕药逐渐被运用于治疗子宫内膜异位症，与孕激素一起被列为一线治疗方案。但长期口服短效避孕药，全身的副反应及血栓风险也会逐渐增加，本研究结果也显示口服避孕药在改善患者痛经程度、缩小子宫体积以及降低血清CA125水平等方面均不如LNG-IUS，因此对于子宫内膜异位症治疗来说，两者均是有效的，但就长期预防和减少不良反应来说，LNG-IUS存在更大的优势，能更好的减轻患者痛经，降低血清CA125水平以及缩小子宫体积。</p><p>本文虽检索了近10年的相关文献，且未限定样本量，但通过阅读题目摘要，且剔除了非随机对照研究，再通过精读文献，剔除不符合纳入标准的文献后，尽管进行了扩大搜索，仍仅纳入17篇研究，且这17篇研究测量指标存在差异，对照组不一致，合并遇到一定困难，某些相关指标报道文献少，因此本文的局限性在于：① 一部分研究方法学模糊，在随机方法以及分配隐藏方法等方面不清楚，导致证据等级不高；② 所纳入文献包括不同对照组，不同的纳入标准，所以导致文章异质性偏大；③ 本文仅包含了中英文文献，未纳入其他语言研究，存在语言偏倚和发表偏倚。</p><p>综上所述，LNG-IUS可明显减轻子宫内膜异位症患者痛经症状，缩小子宫体积，减少月经量，降低血清CA125水平，且价格适宜，不良反应少，对于暂无生育要求，且无LNG-IUS禁忌的患者，可作为首选。但是LUG-IUS虽可缩小子宫体积，因其有脱落风险，不适宜用于子宫体积较大的患者。</p></sec><sec id="s9"><title>文章引用</title><p>张志琼,张觇宇,罗美玲. 左炔诺孕酮宫内释放系统用于治疗子宫内膜异位症的疗效和安全性Meta分析Levonorgestrel Releasing Intrauterine System for the Treatment of Endometriosis: A Meta-Analysis[J]. 临床医学进展, 2021, 11(05): 2456-2466. https://doi.org/10.12677/ACM.2021.115354</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42840-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">李霞, 袁航, 黄文倩, 等. 2018年法国妇产科医师协会/法国国家卫生管理局《子宫内膜异位症管理指南》解读[J]. 中国实用妇科与产科杂志, 2018, 34(11): 1243-1246.</mixed-citation></ref><ref id="hanspub.42840-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Lan, S., Ling, L., et al. (2013) Analysis of the Levonorgestrel-Releasing Intrauterine System in Women with Endometriosis. Journal of International Medical Research, 41, 548-558. &lt;br&gt;https://doi.org/10.1177/0300060513479865</mixed-citation></ref><ref id="hanspub.42840-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Shaaban, O.M., Ali, M.K., Sabra, A.M.A., et al. (2015) Levonorgestrel-Releasing Intrauterine System versus a Low- Dose Combined Oral Contraceptive for Treatment of Adenomyotic Uteri: A Randomized Clinical Trial. Contraception, 92, 301-307. &lt;br&gt;https://doi.org/10.1016/j.contraception.2015.05.015</mixed-citation></ref><ref id="hanspub.42840-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">黄立冬, 吴玉英, 陈昌益, 等. 放置曼月乐环和口服避孕药治疗子宫腺肌病的疗效对比观察[J]. 中国临床新医学, 2018, 11(7): 632-635.</mixed-citation></ref><ref id="hanspub.42840-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">周妍, 葛静. 腹腔镜术后应用左炔诺孕酮宫内节育器治疗子宫内膜异位症临床疗效观察[J]. 临床军医杂志, 2018, 46(2): 159-162.</mixed-citation></ref><ref id="hanspub.42840-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">马晓惠. 宫内节育器曼月乐治疗子宫腺肌病的疗效评价[J]. 河南外科学杂志, 2016, 22(6): 47-48, 49.</mixed-citation></ref><ref id="hanspub.42840-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">金亚玲, 王祥珍. 曼月乐对子宫内膜异位症临床疗效和疼痛的影响[J]. 北方药学, 2020, 17(3): 109-110.</mixed-citation></ref><ref id="hanspub.42840-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">刘志红. 曼月乐和口服避孕药治疗卵巢子宫内膜异位症复发的效果研究[J]. 中外医学研究, 2017, 15(17): 18-19.</mixed-citation></ref><ref id="hanspub.42840-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">栾莹. 曼月乐环与促性腺激素释放激素类似物治疗子宫内膜异位症的疗效比较[J]. 医学理论与实践, 2020, 33(17): 2871-2872.</mixed-citation></ref><ref id="hanspub.42840-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">黄彦. 曼月乐环治疗子宫腺肌病40例临床疗效观察[J]. 现代诊断与治疗, 2019, 30(24): 4377-4379.</mixed-citation></ref><ref id="hanspub.42840-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">陈小梅. 曼月乐治疗子宫内膜异位症的效用分析[J]. 北方药学, 2020, 17(4): 144-145.</mixed-citation></ref><ref id="hanspub.42840-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">杨益琴. 曼月乐治疗子宫腺肌病41例临床疗效分析[J]. 实用妇科内分泌杂志(电子版), 2017, 4(27): 64-65.</mixed-citation></ref><ref id="hanspub.42840-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">李文娟. 曼月乐治疗子宫腺肌病的临床分析[J]. 中国现代药物应用, 2019, 13(24): 184-186.</mixed-citation></ref><ref id="hanspub.42840-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">蓝继常. 曼月乐治疗子宫腺肌症的临床疗效和安全性[J]. 实用妇科内分泌电子杂志, 2019, 6(35): 26-27.</mixed-citation></ref><ref id="hanspub.42840-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">廖红, 程玉芬, 艾小燕, 等. 曼月乐治疗子宫腺肌症的临床疗效和安全性分析[J]. 现代医院, 2019, 19(11): 1671-1673.</mixed-citation></ref><ref id="hanspub.42840-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">王海清, 胡杏军, 刘芳, 等. 优思明及曼月乐对子宫内膜异位症的疗效比较[J]. 中国妇幼健康研究, 2018, 29(5): 652-655.</mixed-citation></ref><ref id="hanspub.42840-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">王红, 郭春颖. 优思明及曼月乐对子宫内膜异位症的临床疗效比较[J]. 海峡药学, 2019, 31(5): 234-235.</mixed-citation></ref><ref id="hanspub.42840-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">丁秀娟, 亓露. 子宫内膜异位症术后应用曼月乐巩固治疗的效果分析[J]. 现代诊断与治疗, 2019, 30(20): 3572-3573.</mixed-citation></ref><ref id="hanspub.42840-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">王笑妍, 韩旭. 子宫腺肌病病灶切除术联合曼月乐环及GnRH-a治疗的比较研究[J]. 医学研究杂志, 2019, 48(6): 148-151+156.</mixed-citation></ref><ref id="hanspub.42840-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Hurskainen, R. (2004) Clinical Outcomes and Costs with the Levonorgestrel-Releasing Intrauterine System or Hysterectomy for Treatment of Menorrhagia. JAMA, 291, 1456-1463. &lt;br&gt;https://doi.org/10.1001/jama.291.12.1456</mixed-citation></ref><ref id="hanspub.42840-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Heikinheimo, O. and Gemzell-Danielsson, K. (2012) Emerging Indications for the Levonorgestrel-Releasing Intrauterine System (LNG-IUS). Acta Obstetricia et Gynecologica Scandinavica, 91, 3-9.  
&lt;br&gt;https://doi.org/10.1111/j.1600-0412.2011.01303.x</mixed-citation></ref></ref-list></back></article>